Biosight is dedicated to providing hope and cure to cancer patients around the world

​

We seek to develop advanced therapeutics to enable safer and more effective treatment for life-threatening diseases, to improve the outcome and quality of life for patients with cancer and related diseases

Innovative Therapeutics

for Oncology & Hematological Disorders  

>>Biosight Presents Updated Clinical Data from Ongoing Phase 2b Study of Aspacytarabine (BST-236) in an Oral Presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

>>Biosight Appoints Dr. Darrel Cohen as Chief Medical Officer

>>Biosight Completes Enrollment in Phase 2b Study of Aspacytarabine (BST-236) for First-Line Acute Myeloid Leukemia Therapy

>>Biosight Receives Orphan Medicinal Product Designation from EMA for Aspacytarabine (BST-236) for AML Treatment
>>Biosight Closes $46M Series C Financing to Advance Clinical Oncology Programs

BIOSIGHT logo .png

  • Home

  • About

    • Overview
    • Board of Directors
    • Management Team
    • Clinical Advisory Board

  • Pipeline

    • Aspacytarabine (BST-236)
    • Publications
    • Intellectual Property

  • For Patients

  • For Clinicians

  • News

  • Contact

  • More

    © 2018 by BioSight Ltd.

    • LinkedIn Social Icon